Pacific Edge
Pacific Edge is a global cancer diagnostics company focused on developing and commercializing bladder cancer diagnostic and prognostic tests. Their key product, Cxbladder, is a suite of non-invasive genomic urine tests used for risk stratification, rule-out, and surveillance of urothelial bladder cancer. The company operates directly in New Zealand, Australia, Singapore, and the United States, and through distributors in other regions.
Short position
Pacific Edge (ASX:PEB) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,063,942 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. PEB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Pacific Edge (PEB) short interest history
PEB Short Interest History
- 30-day change
- -0.00pp
- 90-day change
- -0.00pp
- 1-year change
- -0.02pp
- All-time high
- 0.13% (August 2024)
- All-time low
- 0.01% (February 2022)
Is PEB heavily shorted?
Not especially: 0.09% short interest is modest by ASX standards, ranking #461 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has PEB's short interest changed recently?
Over the past 30 days Pacific Edge's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.09% of shares on issue.
What is the highest PEB's short interest has been?
Since 2022, Pacific Edge's short interest peaked at 0.13% in August 2024 and bottomed at 0.01% in February 2022.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2022. See our methodology.